Skip to main content
NANOVIRICIDES, INC. logo

NANOVIRICIDES, INC. — Investor Relations & Filings

Ticker · NNVC ISIN · US6300873022 LEI · 5493003CK9Y2H0OORR73 US Professional, scientific and technical activities
Open in API
Filings indexed 536 across all filing types
Latest filing 2010-05-20 Interim / Quarterly Rep…
Country US United States of America
Listing US NNVC

About NANOVIRICIDES, INC.

https://www.nanoviricides.com/

NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing a novel class of nanomedicine-based antiviral therapeutics. The company's proprietary platform technology creates "nanoviricides," which are designed to be broad-spectrum drugs that viruses cannot easily evade through mutation. The technology is biomimetic, mimicking the host cell receptors that viruses use for entry. A nanoviricide is engineered to attract and bind to a virus particle, subsequently trapping and dismantling it to neutralize the threat. The company's development pipeline targets a wide range of viral infections, including respiratory viruses such as RSV, influenza, and coronaviruses, as well as herpesviruses (shingles, cold sores), HIV, and hemorrhagic fever viruses.

Recent filings

Filing Released Lang Actions
NANOVIRICIDES 10-Q 3-31-2010
Interim / Quarterly Report 9M 2010
2010-05-20 English
Regulatory Filings 2010
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company, NanoViricides, Inc., was unable to file its periodic report (Form 10-Q for the period ended March 31, 2010) on time due to inability to compile necessary financial information. The document is a notification about the delay and not the actual financial report itself. The length is 4444 characters, which is relatively short and consistent with a notification form rather than a full report. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document notifying the SEC of a late filing, not the report itself.
2010-05-14 English
NANOVIRICIDES 8-K 5-12-2010
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 12, 2010, reporting the entry into a material definitive agreement related to the offering and sale of Series B Convertible Preferred Stock. It details the terms of the securities purchase agreement, the placement agency agreement, and the financial terms of the offering. The content focuses on financing activities, including the issuance of preferred stock and related agreements. There are no financial statements or comprehensive financial performance data typical of annual or quarterly reports. The document is not a report publication announcement or a certification but a current report on a material event related to capital raising. Therefore, the filing type corresponds to Capital/Financing Update (CAP). The document length (7421 characters) supports it being a substantive filing rather than a brief announcement.
2010-05-12 English
NANOVIRICIDES, INC 424B5 5-12-2010
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an offering of Series B Convertible Preferred Stock and Common Stock by NanoViricides, Inc. It details the terms of the offering, pricing, use of proceeds, risk factors, and other information relevant to the securities issuance. This type of document is a capital raising disclosure and fits the category of Capital/Financing Update filings. It is not an annual report, earnings release, or any other report type but specifically a financing prospectus supplement.
2010-05-12 English
Regulatory Filings 2010
Regulatory Filings
2010-04-30 English
Regulatory Filings 2010
Regulatory Filings Classification · 95% confidence The document is a letter from the CEO of NanoViricides, Inc. to the SEC regarding a Registration Statement on Form S-3 filed earlier. It requests acceleration of the effective date of the Registration Statement and acknowledges responsibilities related to the filing. The document is a correspondence related to a regulatory filing, specifically about a registration statement, and does not contain financial data, report content, or detailed disclosures itself. It is a regulatory communication rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Regulatory Filings (RNS). The document length is short and it is a letter, not a report or announcement of a report publication, so it is not RPA.
2010-04-28 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.